Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results From the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) Studies
Response to Ng et al.
- Samy Hadjadj, MD, PHD12,
- Ronan Roussel, MD, PHD345,
- Michel Marre, MD, PHD345 and
- for the DIABHYCAR, DIAB2NEPHROGENE, AND SURDIAGENE study groups
- 1Centre Hospitalier Universitaire Poitiers, Endocrinology, Diabetology and Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France
- 2INSERM, U927, Poitiers, France
- 3INSERM, U695, Xavier Bichat Faculty of Medicine, Paris, France
- 4Unité de Formation et de Recherche Médecine Xavier Bichat, Université Paris seven Diderot, Paris, France
- 5Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Endocrinologie-Diabetologie-Nutrition, Paris, France
- Corresponding author: Samy Hadjadj, s.hadjadj{at}chu-poitiers.fr
Doctor Daniel P.K. Ng (1) was surprised by our reporting of a higher incidence of end-stage renal failure (ESRD) among the participants of the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study with the ACE II genotype than among those without the genotype given that he had published a large, case-control–based meta-analysis supporting the idea that this genotype protects people with …
